News & Updates
Filter by Specialty:
Maintenance olaparib confers survival benefit for HRD+ ovarian cancer patients
In the final overall survival (OS) analysis of the phase III PAOLA-1*/ENGOT-ov25 trial, the addition of olaparib to bevacizumab provided a survival benefit for women with newly diagnosed advanced ovarian cancer with HRD**-positive (HRD+) tumours.
Maintenance olaparib confers survival benefit for HRD+ ovarian cancer patients
19 Dec 2022
One in eight adults experiences long COVID
One in every eight individuals who has experienced COVID-19 may have persistent symptoms 3–5 months post-infection, according to an observational study from the Netherlands.
One in eight adults experiences long COVID
18 Dec 2022
Study reinforces guideline to avoid prescribing EIASMs in glioma patients with epilepsy
First-line monotherapy with levetiracetam appears to have a more favourable effectiveness than enzyme-inducing antiseizure medications (EIASMs) in glioma patients with epilepsy, owing to lower treatment failure for any reason and better tolerability, according to a study, which supports the current neuro-oncology recommendations to avoid EIASMs in this population.
Study reinforces guideline to avoid prescribing EIASMs in glioma patients with epilepsy
17 Dec 2022
Novel topical dexamethasone formulation reduces inflammation, pain after cataract surgery
OCS-01, a topical dexamethasone 1.5% in a novel formulation, appears to be safe and effective in the management of inflammation and pain following cataract surgery, a study has found.
Novel topical dexamethasone formulation reduces inflammation, pain after cataract surgery
17 Dec 2022
Sotorasib improves PFS over docetaxel in KRASG12C-mutated advanced NSCLC
The first-in-class KRASG12C inhibitor sotorasib significantly improved progression-free survival (PFS) in patients with previously treated non-small cell lung cancer (NSCLC) with KRASG12C mutations, according to results of the phase III CodeBreaK 200 trial presented at ESMO 2022.